Longevity has suddenly become one of the hottest areas in technology and healthcare. Billionaires, pharmaceutical companies, AI startups, and venture capital firms are pouring billions into the idea that humans may one day live not just longer, but healthier lives. And as the race to live to 120 heats up, one field may be the unexpected winner: bioprinting.

Indeed, hidden inside that push to live longer and better lives is one of the most ambitious goals in modern medicine: using bioprinting to create human tissues, regenerative implants, blood vessels, and, eventually, fully functional organs.

But let’s not get ahead of ourselves quite yet. Fully printed human organs remain a distant goal. Several startups have struggled to scale. Others have shifted focus toward tissue models, drug testing, or regenerative implants instead of the more irresistible science-fiction visions of replacement hearts and kidneys. But now, a much bigger trend may be changing the picture.

Longevity.